9 completed, 5 active not recruiting, 2 recruiting, 2 terminated. 19 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Completed 9, Active not recruiting 5, Recruiting 2, Terminated 2, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Lupron: new trials by email Literature Review of Lupron trials Research Report on Lupron
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study Darolutamide, Goserelin Acetate, Leuprolide Acetate - Prostate Carcinoma | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 27 | 2021-03-01 | 2026-07-28 |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 804 | 2020-10-08 | 2026-08-19 |
| GnRH Agonist at Embryo Transfer: IVF Outcomes Saline Solution for Injection, Leuprolide Acetate - Infertility, Infertility, Female | Phase 3 | Withdrawn | Maimonides Medical Center | 2019-04-15 | 2019-04-16 | |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Abiraterone, Bicalutamide, Degarelix - Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 1273 | 2018-09-24 | 2026-10-08 |
| Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery Bicalutamide, Degarelix, Docetaxel - Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7 | Phase 2 / Phase 3 | Active not recruiting | NRG Oncology | 612 | 2017-04-05 | 2026-09-14 |
| Management of Castration-Resistant Prostate Cancer with Oligometastases Leuprolide Acetate, Goserelin Acetate, Triptorelin - Castration-resistant Prostate Cancer Patients with Oligometastases | Phase 2 / Phase 3 | Active not recruiting | Sir Mortimer B. Davis - Jewish General Hospital | 102 | 2016-10-01 | 2024-12-04 |
| Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label - Hormone Sensitive Prostate Cancer, Prostate Cancer | Phase 3 | Active not recruiting | Pfizer | 1068 | 2014-12-17 | 2026-10-26 |
| S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer anastrozole, everolimus, exemestane - Breast Cancer | Phase 3 | Active not recruiting | SWOG Cancer Research Network | 1939 | 2013-09-12 | 2026-10-23 |
| Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty Leuprolide Acetate 3 Month Depot - Precocious, Leuprolide Acetate | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 72 | 2008-12-01 | 2014-01-09 |
| A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty Leuprolide acetate 11.25 mg, Leuprolide acetate 30 mg - Puberty, Precocious | Phase 3 | Completed | Abbott | 84 | 2008-06-01 | 2011-11-02 |
| Prevention of Obesity in Women Via Estradiol Regulation leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training - Obesity | Phase 3 | Completed | University of Colorado, Denver | 79 | 2008-05-01 | 2025-04-01 |
| A Study of Leuprolide to Treat Prostate Cancer Leuprolide acetate - Formulation A, Leuprolide acetate - Formulation B - Prostate Cancer | Phase 3 | Completed | Abbott | 310 | 2008-02-01 | 2011-07-19 |
| A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy Degarelix 80 mg / Degarelix 80 mg, Degarelix 160 mg / Degarelix 160 mg, Leuprolide 7.5 mg / Degarelix 80 mg - Prostate Cancer | Phase 3 | Completed | Ferring Pharmaceuticals | 386 | 2007-03-01 | 2013-03-21 |
| The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer Degarelix, Leuprolide 7.5 mg - Prostate Cancer | Phase 3 | Completed | Ferring Pharmaceuticals | 620 | 2006-02-01 | 2012-12-19 |
| External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer Radiation Therapy, Bicalutamide, Leuprolide - Prostate Cancer | Phase 3 | Terminated | M.D. Anderson Cancer Center | 39 | 2005-02-01 | 2012-08-08 |
| Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial External beam radiation, Lupron, Casodex - Prostate Cancer | Phase 3 | Terminated | Schiffler Cancer Center | 6 | 2004-08-01 | 2016-04-14 |
| Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Casodex, Eulexin, LHRH agonist - Prostate Cancer | Phase 3 | Completed | Radiation Therapy Oncology Group | 1579 | 2000-02-01 | 2022-06-15 |
| Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer flutamide, Zoladex, Lupron - Prostate Cancer | Phase 3 | Completed | Radiation Therapy Oncology Group | 2028 | 1994-10-01 | 2018-06-14 |
| Study of Lupron Depot In The Treatment of Central Precocious Puberty Lupron (leuprolide acetate) - Puberty, Precocious | Phase 3 | Completed | Abbott | 55 | 1991-01-01 | 2011-04-12 |
Prostatic Neoplasms (11) · Puberty, Precocious (3) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Disease Susceptibility (1) · Infertility (1) · Infertility, Female (1) · Infertility, Male (1) · Metabolic Syndrome (1) · Obesity (1)
Abbott (3) · ECOG-ACRIN Cancer Research Group (2) · Ferring Pharmaceuticals (2) · Radiation Therapy Oncology Group (2) · SWOG Cancer Research Network (2) · AbbVie (prior sponsor, Abbott) (1) · M.D. Anderson Cancer Center (1) · Maimonides Medical Center (1) · NRG Oncology (1) · Pfizer (1) · Schiffler Cancer Center (1) · Sir Mortimer B. Davis - Jewish General Hospital (1) · University of Colorado, Denver (1)
United States (18) · Canada (7) · Puerto Rico (6) · Mexico (3) · Netherlands (3) · United Kingdom (3) · Czechia (2) · Germany (2) · Hungary (2) · Romania (2) · Russia (2) · Ukraine (2) · Australia (1) · Austria (1) · Brazil (1)
Alicia K Morgans (1) · Andrew K. Lee, MD (1) · Antonios Likourezos, M.P.H., M.A. (1) · Brian Chapin (1) · David G. McGowan, MD (1) · Gregory S Merrick, MD (1) · John Sylvester, MD (1) · Kent E. Wallner, MD (1) · Kristof Chwalisz, MD (1) · Kristof Chwalisz, MD, PhD (1) · Mariana Chavez-MacGregor, MD, MSc (1) · Mark D Hurwitz (1) · Michael G. Haddock, MD (1) · Neha Vapiwala (1)
PMID 34350976, PMID 38320143, PMID 38421243, PMID 19035858, PMID 21751904, PMID 21860633, PMID 22025196, PMID 22344198, PMID 24926950, PMID 25534388, PMID 29631362, PMID 34385241, PMID 34481017, PMID 37119051, PMID 37851874, PMID 38320501, PMID 38421252, PMID 38833643, PMID 39621968, PMID 40140551, PMID 40907514, PMID 41124201, PMID 41349040, PMID 41364813, PMID 41824265, PMID 42333826
U10CA180820 (2), R01AG018198 (1), U10CA032102 (1), U10CA180868 (1), U10CA180888 (1)